Correction of Farsightedness in Children Study (CHICS)
Correction of Hyperopia in Children Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Illinois College of Optometry/Illinois Eye Institute
-
-
New York
-
New York, New York, United States, 10036
- SUNY College of Optometry/University Optometric Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- Southern College of Optometry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 6-11 years;
- At least +1.00D Hyperopia (farsightedness);
- < +4.00D Hyperopia;
- < 1.00D Astigmatism;
- < 1.00D Anisometropia (difference between the two eyes);
- Willing to be randomized;
- Best corrected visual acuity of 20/25 or better in each eye;
- Willing to wear eyeglasses full-time;
- Willing to return for follow-up visits
Exclusion Criteria:
- Previous wear of glasses or contacts for farsightedness/hyperopia;
- Eye disease that affects visual function;
- Amblyopia (lazy eye);
- Strabismus (eye turn);
- History of strabismus surgery;
Chronic use of any of the following medications:
- Antianxiety agents (Librium, Valium)
- Antiarrythmic agents (Cifenline, Cibenzoline)
- Anticholinergics (Motion sickness patch - scopolamine)
- Bladder spasmolytic (Propiverine)
- Chloroquine
- Phenothiazines (Compazine, Mellaril, Thorazine)
- Tricyclic antidepressants (Elavil, Nortriptyline, Tofranil)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Spectacles
Spectacles with hyperopic lenses
|
Hyperopic spectacle lenses
|
|
Placebo Comparator: Control
Spectacles with placebo lenses
|
Plano (no power, control) spectacle lenses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Kaufman Test of Educational Achievement (K-TEA) Reading Comprehension Score as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction)
Time Frame: 6 week outcome exam
|
The Kaufman Test of Educational Achievement (K-TEA) was used to measure change in reading skill (reading comprehension).
The K-TEA is a well-established, individually administered, standardized test for assessment of achievement in reading, with a mean standard score of 100 and standard deviation of 15.
Higher values represent better performance.
|
6 week outcome exam
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cognitive Assessment System (CAS) Attention Scores as Measured From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction)
Time Frame: 6 week outcome exam
|
Individually administered battery designed to measure cognitive processing abilities. CAS is based on PASS (Planning, Attention, Simultaneous, and Successive), a well-researched cognitive/neuropsychological theory. A higher score indicates a better outcome. |
6 week outcome exam
|
|
Change in Accommodative Response From Baseline to After 6 Weeks of Assigned Treatment (Hyperopic or Control Correction)
Time Frame: 6 week outcome exam
|
Accommodative response, Right eye.
This is a measure the accuracy of focusing (accommodative accuracy or response) while the subject views a near target.
Lower (positive) values represent better accuracy of focusing.
|
6 week outcome exam
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Marjean Kulp, OD, Ohio State University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2001H0401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.